Last reviewed · How we verify
Silver Sulfadiazine (SILVER)
At a glance
| Generic name | SILVER |
|---|---|
| Sponsor | King Pharms Llc |
| Drug class | Sulfonamide Antibacterial [EPC] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- second degree burns
- third degree burns
- wound sepsis
Common side effects
- Leukopenia
- Skin necrosis
- Erythema multiforme
- Skin discoloration
- Burning sensation
- Rashes
- Interstitial nephritis
- Delayed separation
Key clinical trials
- The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants (NA)
- Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia (NA)
- Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns (PHASE2)
- Intervascular Post-Market Clinical Follow-Up (PMCF) Registry
- Clinical Registry Collecting Real World Evidence on Wound Care Treatments
- A Bioelectric Dressing for Post De-Roofing Treatment of HS (NA)
- Preventing Early Childhood Caries With a Silver Diamine Fluoride Gel (PHASE2)
- Arresting Early Childhood Caries With a Silver Diamine Fluoride Gel (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |